Ovarian, Fallopian Tube, & Primary Peritoneal Cancer Prevention (PDQ®)—Health Professional Version - National Cancer Institute

Ovarian, Fallopian Tube, & Primary Peritoneal Cancer Prevention (PDQ®)—Health Professional Version - National Cancer Institute

Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Prevention (PDQ®)–Health Professional Version

OVARIAN, FALLOPIAN TUBE, AND PRIMARY PERITONEAL CANCER

• Patient
• Health Professional
  • Ovarian Epithelial, Fallopian Tube, & Primary Peritoneal Cancer Treatment
  • Ovarian Germ Cell Tumors Treatment
  • Ovarian Low Malignant Potential Tumors Treatment
  • Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Prevention
  • Ovarian, Fallopian Tube, & Primary Peritoneal Cancer Screening
• Research

SECTIONS

• Who Is at Risk?
• Overview
• Description of the Evidence
• Changes to This Summary (07/​27/​2017)
• About This PDQ Summary
• View All Sections

Changes to This Summary (07/27/2017)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Overview

Added text to state that ovarian cancer risks associated with current or recent hormone therapy did not differ by preparation type (cited Mørch et al. as reference 1 and Beral et al. as reference 2).

This summary is written and maintained by the PDQ Screening and Prevention Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Description of the Evidence

Next section >
About This PDQ Summary

• Updated: July 27, 2017